Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a promising biotech company with a strong portfolio of approved and pipeline drugs, focusing on the treatment of various cancers. The company's flagship drug Brukinsa is a significant revenue generator, with two other commercialized drugs in their portfolio. With a global presence and a strong focus on research and development, BeOne Medicines has the potential for significant growth and success in the future.

Bears say

BeOne Medicines is facing intense competition in the oncology therapeutics market from established players such as AbbVie and AstraZeneca. While the company's flagship product, Brukinsa, has shown promising results and contributed significantly to the company's revenue, its other two drugs generate revenue mainly from China, posing a risk of over-reliance on the Chinese market. The company's pipeline of over 50 drugs in clinical trials could potentially diversify its revenue streams in the long term, but it remains to be seen if these drugs will achieve regulatory approval and commercial success. Overall, the company's dependence on a single product and its heavy focus on the Chinese market are reasons for a negative outlook on its stock.

BeiGene Ltd (ONC) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 13 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $405.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $405.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.